Mycophenolic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Mycophenolic Acid
- Pharmacist Assessment Report
- Mycophenolic Acid: From Immunosuppression in Transplantation to Hemoglobinopathy
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Mycophenolic Acid: From Immunosuppression in Transplantation to Hemoglobinopathy
One-Sentence Summary
Mycophenolic acid is an immunosuppressant that inhibits lymphocyte proliferation. It is marketed in Canada, but the data compiled for this report do not list an approved indication. The TxGNN model predicts it may be effective for hemoglobinopathy, supported by 1 clinical trial (indirect relevance only) and 1 publication. The evidence is weak and indirect: the likely role is as transplant-related immunosuppression (GVHD prophylaxis) in thalassemia, not treatment of the underlying red cell disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report (licence indication text is empty) |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 0.9960 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 8 of 8) |
| Number of DINs | 8 (marketed: 8) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the compiled data. Based on known pharmacology, mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme needed for de novo guanine nucleotide synthesis. This suppresses the proliferation of T and B lymphocytes.
In hemoglobinopathies such as thalassemia, this mechanism is relevant mainly in allogeneic hematopoietic stem cell transplantation, where immunosuppression helps prevent graft-versus-host disease (GVHD). It does not act on the underlying red cell defect. A 2025 publication on off-label mycophenolate mofetil (the prodrug of mycophenolic acid) dosing in children with thalassemia undergoing transplantation suggests this use occurs in practice.
The prediction is therefore best read as support for a transplant-setting research question, not as evidence of disease-modifying activity.
Other high-scoring predictions have little support:
- Rheumatoid arthritis (score 0.9918, L3): the mechanism is biologically plausible, and older literature from 1991–1999 describes mycophenolate as investigational for this disease. No efficacy RCTs were identified.
- Migraine, rare red cell enzyme or membrane disorders, antithrombin deficiency, chromosomal deletion: model prediction only (L5), with no plausible mechanistic link in the supplied data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02342145 | Phase 4 | Completed | 205 | Basiliximab for prevention of acute GVHD in unrelated allogeneic stem cell transplantation for thalassemia major. The tested drug is basiliximab, not mycophenolic acid, so this is indirect evidence only. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39891881 | 2025 | Cohort / population PK | Eur J Drug Metab Pharmacokinet | Population pharmacokinetic model and dosing simulation for off-label mycophenolate mofetil in children with thalassemia undergoing stem cell transplantation, to fill the gap in dosing guidance. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02372746 | APO-MYCOPHENOLIC ACID | Not listed | Not listed |
| 02372738 | APO-MYCOPHENOLIC ACID | Not listed | Not listed |
| 02518538 | JAMP MYCOPHENOLIC ACID | Not listed | Not listed |
| 02264560 | MYFORTIC | Not listed | Not listed |
| 02511673 | MAR-MYCOPHENOLIC ACID | Not listed | Not listed |
All 8 licences are valid single-ingredient products; the table shows the first 5.
Safety Considerations
- Drug Interactions: 100 interactions were found in the DDI query; the 20 retrieved include one major, many moderate and a few minor.
- Major: activated charcoal.
- Moderate: antacids and mineral products (magnesium oxide, magnesium hydroxide, magnesium carbonate, magaldrate, aluminum hydroxide, calcium carbonate); tetracycline-class antibiotics (doxycycline, minocycline, tetracycline); other anti-infectives (amoxicillin, clarithromycin, levofloxacin, metronidazole, vancomycin, kanamycin, paromomycin).
- Minor: zinc sulfate, zinc acetate, iron.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence for hemoglobinopathy is indirect. The only trial tests a different drug (basiliximab), and the only publication is a dosing-modelling study of the prodrug in transplanted thalassemia patients. Any benefit would come from GVHD prophylaxis, not from treating the red cell disease. The package insert safety data are also missing, so safety screening cannot proceed.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap)
- Mechanism of action data (for example, from DrugBank)
- Licence indication text, to establish the original approved indication
- Clinical studies of mycophenolate-containing GVHD prophylaxis regimens specifically in thalassemia or other hemoglobinopathy transplants
- A decision on whether the question should be framed as a transplant-immunosuppression use rather than treatment of hemoglobinopathy itself
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.